SCHEMBL11029564

SCHEMBL11029564

CN1CCN(c2ccc(Nc3cc(Cc4ccc5ccccc5c4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNIK Q9UKE5 4/20 0.52
▸ SLC2A1 P11166 2/20 0.50
▸ STAT6 P42226 1/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ EGFR P00533 1/20 0.47
▸ AURKA O14965 2/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ CDK4 P11802 1/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CCND3 P30281 1/20 0.45
▸ CDK6 Q00534 1/20 0.45
▸ PTK2 Q05397 1/20 0.44
▸ MAP4K1 Q92918 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ TTK P33981 1/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44
▸ SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11025081 0.90 STAT6 (0.55) TNIKSLC2A1STAT6NPC1RAB9A
SCHEMBL11029543 0.87 MAPKAPK2 (0.49) SLC2A1STAT6NPC1RAB9AEGFR
SCHEMBL11027886 0.86 SLC2A1 (0.47) SLC2A1STAT6EGFRAURKACDK2
SCHEMBL11028483 0.86 EGFR (0.49) SLC2A1STAT6NPC1RAB9AEGFR
SCHEMBL11030519 0.86 MAPKAPK2 (0.49) SLC2A1STAT6EGFRAURKACDK2
SCHEMBL11025349 0.86 SLC2A1 (0.52) SLC2A1STAT6RAB9AEGFRAURKA
SCHEMBL11028773 0.86 MAPKAPK2 (0.50) SLC2A1STAT6NPC1RAB9AEGFR
SCHEMBL11031933 0.86 MAPKAPK2 (0.51) SLC2A1STAT6EGFRAURKACDK4
SCHEMBL11028029 0.85 CDK4 (0.53) SLC2A1STAT6EGFRAURKACDK2
SCHEMBL11029481 0.85 SLC2A1 (0.52) SLC2A1STAT6EGFRAURKACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 TNIK 717/4885SLC2A1 3662/4885STAT6 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback